Compare MGM Resorts International (MGM) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Novavax Inc — how do they compare? MGM Resorts International trades at $45.97 (market cap $11.86B), while Novavax Inc trades at $8.05 (market cap $1.30B). The key difference: MGM Resorts International is far larger — about 9.1× Novavax Inc's market cap, and MGM Resorts International pays a 0.03% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| MGM | NVAX | |
|---|---|---|
Market Cap | $11.86B | $1.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $11.19 |
52-Week Low | $30.72 | $6.22 |
Enterprise Value | $40.90B | $800.50M |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $46.55, up 0.91% today, amid ongoing acquisition talks with Barry Diller's People Inc. at $48.30 per share. The stock shows mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, revenue grew to $17.54B in 2025, though net income margin compressed to 1.03%. Analyst consensus is evenly split between Buy and Hold, with a $48.93 price target suggesting modest upside from current levels.
MGM's outlook is clouded by acquisition uncertainty and declining profitability, offset by potential takeover premium and stable revenue. Key risks include execution on margin improvement, high debt levels, and macroeconomic sensitivity. The stock presents a speculative opportunity tied to deal completion, with fundamental challenges requiring careful monitoring.
Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.
The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
